Evidence map›Paper›PMID 34577006›Full record

ArticleMolecules (Basel, Switzerland)2021

Oscar A Lenis-Rojas, Sandra Cordeiro, Marta Horta-Meireles, Jhonathan Angel Araujo Fernández, Sabela Fernández Vila, Juan Andrés Rubiolo, Pablo Cabezas-Sainz, Laura Sanchez, Alexandra R Fernandes, Beatriz Royo

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 4 countries.

Oscar A Lenis-RojasITQB NOVA, Instituto de Tecnologia Química e Biológica António Xavier, Av. da República, 2780-157 Oeiras, Portugal.
Sandra CordeiroUCIBIO, Departamento Ciências da Vida, NOVA School of Science and Technology, NOVA University, Campus de Caparica, 2829-516 Caparica, Portugal.
Marta Horta-MeirelesITQB NOVA, Instituto de Tecnologia Química e Biológica António Xavier, Av. da República, 2780-157 Oeiras, Portugal.
Jhonathan Angel Araujo FernándezDepartamento de Zoología Genética y Antropología Física, Facultad de Veterinaria, Universidad de Santiago de Compostela, Campus de Lugo, 27002 Lugo, Spain.
Sabela Fernández VilaDepartamento de Zoología Genética y Antropología Física, Facultad de Veterinaria, Universidad de Santiago de Compostela, Campus de Lugo, 27002 Lugo, Spain.
Juan Andrés RubioloDepartamento de Zoología Genética y Antropología Física, Facultad de Veterinaria, Universidad de Santiago de Compostela, Campus de Lugo, 27002 Lugo, Spain.
Pablo Cabezas-SainzDepartamento de Zoología Genética y Antropología Física, Facultad de Veterinaria, Universidad de Santiago de Compostela, Campus de Lugo, 27002 Lugo, Spain.ORCID 0000-0002-7158-4459
Laura SanchezDepartamento de Zoología Genética y Antropología Física, Facultad de Veterinaria, Universidad de Santiago de Compostela, Campus de Lugo, 27002 Lugo, Spain.ORCID 0000-0001-7927-5303
Alexandra R FernandesUCIBIO, Departamento Ciências da Vida, NOVA School of Science and Technology, NOVA University, Campus de Caparica, 2829-516 Caparica, Portugal.ORCID 0000-0003-2054-4438
Beatriz RoyoITQB NOVA, Instituto de Tecnologia Química e Biológica António Xavier, Av. da República, 2780-157 Oeiras, Portugal.ORCID 0000-0002-7909-9992
Universidade de Santiago de Compostela · ESInstituto de Biologia Experimental e Tecnológica · PTUniversidade Nova de Lisboa · PTUniversidade Estadual de Campinas (UNICAMP) · BR

Funding

Fundação para a Ciência e a Tecnologia UIDB/04612/2020 and UIDP/04612/2020, UIDP/04378/2020 , UIDB/04378/2020
6 · The paper itself

Abstract

Cisplatin and its derivatives are commonly used in chemotherapeutic treatments of cancer, even though they suffer from many toxic side effects. The problems that emerge from the use of these metal compounds led to the search for new complexes capable to overcome the toxic side effects. Here, we report the evaluation of the antiproliferative activity of Fe(II) cyclopentadienyl complexes bearing

Indexed as

AnimalsAntineoplastic AgentsCell Line, TumorCell SurvivalCisplatinDrug Screening Assays, AntitumorFibroblastsHeterocyclic CompoundsHumansInhibitory Concentration 50Iron CompoundsMethaneNeoplasmsXenograft Model Antitumor AssaysZebrafishAntineoplastic AgentscarbeneCisplatinHeterocyclic CompoundsIron CompoundsMethaneanticancer activityiron(II)–NHC complexesN-heterocyclic carbenezebrafish

Identifiers

PMID34577006
PMCPMC8470334
OpenAlexW3199860680

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.